[Extreme hypoglycemia during combined tolbutamide, n-1-butylbiguanide hydrochloride and chloramphenicol therapy].
D000367:Age Factors; D000368:Aged; D001645:Biguanides / Q000009:adverse effects*; D002701:Chloramphenicol / Q000009:adverse effects*; D003920:Diabetes Mellitus / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000188:drug therapy; D003928:Diabetic Nephropathies / Q000188:drug therapy; D004357:Drug Synergism; D005260:Female; D005947:Glucose / Q000627:therapeutic use; D006333:Heart Failure / Q000150:complications; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced* / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D002537:Intracranial Arteriosclerosis / Q000188:drug therapy; D014044:Tolbutamide / Q000009:adverse effects*
D001645:Biguanides; D007004:Hypoglycemic Agents; D002701:Chloramphenicol; D014044:Tolbutamide; D005947:Glucose
Extreme Hypoglykämie unter kombinierter Behandlung mit Tolbutamid, n-1-Butylbiguanidhydrochlorid und Chloramphenikol.